Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Your second paragraph is not accurate and significantly mischaracterizes what I said to callers, so it was a good place to stop reading.
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
3/31 is a Saturday.
I expect filing this week.
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
My opinion is of no concern.
Year-end and first quarter financials will be issued soon, which will give investors, potential investors, more to digest.
Paul Knopick
pknopick@eandecommunications.com
Still here.
Stay tuned for 10K this week.
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
Year-end financial report (10K) has been in March (at least) the last two years. Outstanding shares are disclosed with the quarterly reports.
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
Love to see it!
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
We cannot understand the ways of the DTCC either. I can tell you that they have NOT contacted the company about any chill; I can tell you that trading is going smoothly, except for a hiccup at Zecco. How else can I put this?
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
Thanks for very intelligent post.
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
Exactly!
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
I have answered the question one-half dozen times. We are aware of no chill, DTCC has advised us of no chill, we have talked to everyone we need to talk to, and market is working smoothly, except for Zecco, and I can't speak for them.
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
Stem cell advances:
Breakthrough Therapy Using Cord Blood Banking Driving Stem Cell Industry
Five Star Equities Provides Stock Research on Cord Blood America & Aastrom Biosciences
NEW YORK, NY, Jan 24, 2012 (MARKETWIRE via COMTEX) -- Given some positive trends, the stem cell market could be set to skyrocket this year. A recent report from Kalorama Information titled "Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development," estimates that the market for stem cell technologies will rise to over $700 million this year and could reach over $1 billion. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on Cord Blood America Inc. (OTCBB: CBAI) and Aastrom Biosciences Inc. (NASDAQ: ASTM). Access to the full company reports can be found at:
www.fivestarequities.com/CBAI
www.fivestarequities.com/ASTM
Kalorama finds that cell therapies are largely confined to a few conditions. Oncological conditions such as leukemia, multiple myeloma and non-Hodgkins lymphoma are some of the most popular areas of research, although certain non-cancerous diseases like aplastic anemia, immunodeficiency and lupus are also increasingly addressed with stem cells.
Kalorama finds that cord blood banking is a source of revenue growth in the stem cell market. U.S. researchers are currently undergoing a phase I safety study using a child's umbilical cord blood stem cells to try to restore hearing loss. "This study is exciting because it might offer a non-surgical option for some children with profound hearing loss," explains Dr. James Baumgartner, sponsor of the study and guest research collaborator at The University of Texas Health Science Center at Houston Medical School.
Five Star Equities releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.fivestarequities.com and get exclusive access to our numerous stock reports and industry newsletters.
Stem cells from umbilical cords do not pose an ethical dilemma because the cells come from a source that would otherwise be discarded, Science Daily reports. Recent studies suggest that stem cells from umbilical cords have been converted into other types of cells, which may eventually lead to new treatment options for nervous system diseases. "This is the first time this has been done with non-embryonic stem cells," says James Hickman, a University of Central Florida bioengineer and leader of the research group.
Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:
www.fivestarequities.com/disclaimer
Contact:
Five Star Equities
Email Contact
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
No chill.
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
We see no evidence of a chill, we have not been told of a chill and except for Zecco, the market is working fine.
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
All trades (other than Zecco) performing normally. No evidence of a "chill." No correspondence to company. DTCC and on-line brokerages are always a fountain of misinformation; they just want to get you off the line.
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
Agree!
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
As of last time I talked to CBAI earlier today, CBAI has not been notified by DTCC of any "chill." There has been no phone call, no letter, no e-mail, no writing in the sky. However, I did hear from a shareholder about problems with Zecco (which appears to be the only brokerage impacted; although if I'm wrong, and there are more, I apologize. But I have heard of no others) and I now have heard anecdotal statements that those calling DTCC are told there is a "chill." (There are many different varieties, fyi.)
Truly, how can they "chill" a company and not tell them? Fiendish. I am trying to get you (and others) a definitive answer.
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
No, they were not.
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
Francis is an IPO expert, Harvard MBA, and does frequent interviews with the top financial journalists. He does CEO interviews for me. He does not do an analyst report, he does interview the CEO and the interview in full is issued with a news release.
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
Sorry, I don't find a question herein.
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
I answer every legitimate question I have the time to get to herein. I believe I have answered you numerous times. You might
not like the answer, or agree with it, but I try.
I answer essentially every e-mail I receive and every phone call.
What I'm not going to do is to return to issues that have been hashed and re-hashed. The Company has said all it is going to say about many of these issues, so there is no point.
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
We were talking about Zecco. I'm not here to review ancient history. I have dealt with hundreds of CEOs over my years and rarely found one with the integrity, energy and smarts of Matt Schissler. You can try to drag him down with some claim about this or that, but what he's done is go from an idea to an international company, with a state-of-the-art facility in Las Vegas, in one of the best sectors in the medical arena. Top-notch job!
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
This has all been asked and answered. Enough!
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
I didn't speak to anyone. CBAI management did. Sorry if that was unclear. There is no chill in place on CBAI at this time (and hopefully never again). Zecco is working from an outdated list. Zecco says the one man who can clear this up does not "talk to the public." We will keep trying.
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
You could be right. I just get the itch every now and again to go at it with people who are cheering for this company to fail.
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
I don't bother my clients with hearsay and nonsense.
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
Indeed the examples I gave you are what happens to CBAI, in many different ways, every day.
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
I was at the grand opening. No such statement was made to the investors.
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
I truly do not care who said what when. Neither is an official representative of CBAI. I know what I've heard from Matt numerous times on this issue. Period.
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
Let's say you owned a business, say a restaurant. And you had a nice restaurant. But a competitor was wildly jealous. So they started calling the Board of Health leaving anonymous tips about seeing rats in your back area. They made sure to take a dump on your front stoop before you arrived in the a.m. They called the newspaper urging them to investigate a rash of food poisoning at your place. And on and on. And you'd put up with this??
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
I've put it to rest.
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
Your question is essentially unanswerable in that (a) I don't know who these people are whom you reference and (b) I don't know if they now have an ax to grind. I do know I've discussed this issue many times with Matt and he never, ever, said the words you place in his mouth. That's what I care about, not hearsay evidence.
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
Truly what good does it do talking to you if you don't believe the simplest of statements? Just the other day we had one of the professionals bashers herein write a major tissue bank company fishing for information. No company has to stand for that!
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
Well, I said I'd answer the "legitimate" questions. This one certainly doesn't fit that category.
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
I appreciate your "concern" about our web site. Top priority is servicing current clients.
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
CBAI is an OTC BB company, not an OTC (Pink). With its current share price, there is no opportunity to move it to AMEX or NASDAQ, for instance. Can you rewrite history, take away the 8-week DTCC chill that did enormous damage, and let's see what happens then.
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
There is no chill in place.
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
I just try to answer legitimate questions that are asked.
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
I posted twice on this already. Please note those posts. The answer to your question is Yes.
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
Well, thank you very much for the kind words. Indeed an investor brought this to our attention and we're trying to fix it. Zecco says only their Operations Manager can make a change and the Operations Manager does not talk to the public. Catch 22. But we'll keep trying.
Paul Knopick
pknopick@eandecommunications.com
949.707.5365
I don't know anything about anyone who made that claim: Their motive, who they are, what they are up to. I know I've disussed the issue myriad times with the CEO, and have heard him talk about it many times, and have never heard him say what you claim he said. Period.
Paul Knopick
pknopick@eandecommunications.com
949.707.5365